Enanta制药 ENTA 深 沪
已收盘 12-26 16:00:00 美东时间
16.85
+0.250
+1.51%
华盛通- 最 高16.90
- 今 开16.56
- 成交量 25.13万股
- 最 低 16.1988
- 昨 收 16.60
- 总市值 4.86亿
- 52周最高 17.05
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 4.09
- 委 比 0.13%
- 总股本 2885.29万
- 历史最高 127.77
- 量 比 0.40
- 振 幅 4.22%
- 历史最低 4.09
- 每 手 1
- 风险率 2.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enanta Pharmaceuticals Reports Progress in Drug Development
Enanta Pharmaceuticals ( ($ENTA) ) has released its Q4 earnings. Here is a brea...
11-18 12:02
Enanta Pharma Q4 EPS $(0.87) Beats $(1.03) Estimate, Sales $15.125M Miss $15.956M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.03) by 15.29 percent. This is a 36.03 percent increase over losses of $(1.36) per share from the
11-18 05:02
Earnings Scheduled For November 17, 2025
Companies Reporting Before The Bell • So-Young Intl (NASDAQ:SY) is projected to...
11-17 19:11
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Enanta rises as J.P. Morgan starts at Overweight on RSV therapy
Shares of Enanta Pharmaceuticals traded higher on Friday after two straight sessions of losses as J.P. Morgan launched its coverage with an Overweight recommendation, citing the potential of zelicapav...
11-15 00:54
JP Morgan Initiates Coverage On Enanta Pharma with Overweight Rating, Announces Price Target of $17
JP Morgan analyst Anupam Rama initiates coverage on Enanta Pharma (NASDAQ:ENTA) with a Overweight rating and announces Price Target of $17.
11-14 20:28
W. P. Carey Announces Third Quarter 2025 Financial Results
NEW YORK, Oct. 28, 2025 /PRNewswire/ -- W. P. Carey Inc. (NYSE: WPC) (W. P. Carey or the Company), a net lease real estate investment trust, today reported its financial results for the thir...
10-29 04:05
Entrada Therapeutics to Present at Upcoming Investor Conferences
Entrada Therapeutics announced its participation in two upcoming investor conferences. CEO Dipal Doshi will present at the Jefferies Global Healthcare Conference in London on November 18 and will join a fireside chat at the Evercore Healthcare Conference in Miami on December 3. Live webcasts and 90-day replays will be available on the company's website. Entrada, a clinical-stage biopharmaceutical company, develops novel intracellular therapies fo...
10-28 11:00
Enanta Pharmaceuticals Highlights Promising Zelicapavir Pediatric Results And EDP-323 Post-Exposure Prophylaxis Data For RSV At IDWeek 2025
Zelicapavir Results in Shortened Symptom Duration in Pediatric PatientsEDP-323 is Highly Effective in a Post-Exposure Prophylaxis Setting
10-20 19:04
Enanta Pharmaceuticals to Showcase RSV Drug Data at IDWeek 2025, Highlighting Two Oral Once-Daily Treatments
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for
10-07 19:14
